Yervoy Launch in Europe gets clinicians excited about melanoma combo with Zelboraf
This article was originally published in Scrip
Bristol-Myers Squibb has begun its roll-out of the novel advanced melanoma treatment Yervoy (ipilimumab) in Europe, as Genentech and Plexxikon received their first approvals in the US for another promising treatment, Zelboraf (vemurafenib). The two drugs, which are now being tested for use in combination, are heralding a new era in the treatment of melanoma, ending a period of 30 years' stagnation in drugs for the disease.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.